Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

European Commission May Pursue More Antitrust Actions Against Pharma

This article was originally published in The Pink Sheet Daily

Executive Summary

The EC is scrutinizing pharma practices that may delay generic entry and advocating changes in the patent system.
Advertisement

Related Content

EMA To Share Generics Data To Speed Access, But Pitfalls Remain
EU Commission Misses Chance To Lead On Drug Patent Settlements
EU/U.S. Trade Pact Talks May Stumble Over Drug Regulation, Affordability
Sanofi May Get EU Double Whammy After French Fine For Hindering Entry Of Plavix Generics
EU Transparency Directive Revisions May Accelerate Access To New Medicines, But IP Issues Set To Cause A Storm
Reverse Settlements Are Acceptable Under Certain Conditions, DoJ Says
Reverse Settlements Are Acceptable Under Certain Conditions, DoJ Says
Quelle Surprise! EU Investigators Raid Pharma Firms

Topics

Advertisement
UsernamePublicRestriction

Register

PS069812

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel